Hostname: page-component-78c5997874-t5tsf Total loading time: 0 Render date: 2024-11-17T19:05:12.247Z Has data issue: false hasContentIssue false
  • English
  • Français

GABA and acute psychoses1

Published online by Cambridge University Press:  09 July 2009

Brian Meldrum
Rights & Permissions [Opens in a new window]

Abstract

An abstract is not available for this content so a preview has been provided. As you have access to this content, a full PDF is available via the ‘Save PDF’ action button.
Image of the first page of this content. For PDF version, please use the ‘Save PDF’ preceeding this image.'
Type
Editorial
Information
Psychological Medicine , Volume 12 , Issue 1 , February 1982 , pp. 1 - 5
Copyright
Copyright © Cambridge University Press 1982

References

REFERENCES

Bird, E. D., Barnes, J., Iversen, L. L., Spokes, E. G., Mackay, A. V. P. & Shepherd, M. (1977). Increased brain dopamine and reduced glutamic acid decarboxylase and choline acetyl transferase activity in schizophrenia and related psychoses. Lancet ii, 1157–1159.CrossRefGoogle Scholar
Bird, E. D., Spokes, E. G. S. & Iversen, L. L. (1979). Increased dopamine concentration in limbic areas of brain from patients dying with schizophrenia. Brain 102, 347–360.CrossRefGoogle ScholarPubMed
Bowen, D. M., Smith, C. B., White, P. & Davison, A. N. (1976). Neurotransmitter-related enzymes and indices of hypoxia in senile dementia and other abiotrophies. Brain 99, 459–496.CrossRefGoogle ScholarPubMed
Bowers, M. B. (1974). Central dopamine turnover in schizophrenic syndromes. Archives of General Psychiatry 31, 50–54.CrossRefGoogle ScholarPubMed
Bowery, N. G. & Brown, D. A. (1974). Depolarizing actions of γ-amino-butyric acid and related compounds on rat superior cervical ganglia in vitro. British Journal of Pharmacology 50, 205–218.CrossRefGoogle Scholar
Bowery, N. G., Hill, D. R., Hudson, A. L., Doble, A., Middlemiss, D. N., Shaw, J. & Turnbull, M. (1980). (-)baclofen decreases neurotransmitter release in the mammalian CNS by an action at a novel GABA receptor. Nature 283, 92–94.CrossRefGoogle Scholar
Brennan, M. J. W. & Cantrill, R. C. (1979). δ-aminolaevulinic acid is a potent agonist for GABA autoreceptors. Nature 280, 514–515.CrossRefGoogle ScholarPubMed
Brown, D. A. & Marsh, S. (1978). Axonal GABA-receptors in mammalian peripheral nerve trunks. Brain Research 156, 187–191.CrossRefGoogle ScholarPubMed
Carlsson, A. (1978). Antipsychotic drugs, neurotransmitters and schizophrenia. American Journal of Psychiatry 135, 164–173.CrossRefGoogle ScholarPubMed
Casey, D. E., Gerlach, J., Magelund, G. & Christensen, T. R. (1980). γ-acetylenic GABA in tardive dyskinesia. Archives of General Psychiatry 37, 1376–1380.CrossRefGoogle ScholarPubMed
Chouinard, G. & Jones, B. D. (1978). Schizophrenia as dopamine-deficiency disease. Lancet ii, 99–100.CrossRefGoogle Scholar
Collins, G. G. S. (1980). Release of endogenous amino acid neurotransmitter candidates from rat olfactory cortex slices: possible regulatory mechanisms and the effects of pentobarbitone. Brain Research 190, 517–528.CrossRefGoogle ScholarPubMed
Cross, A. J., Crow, T. J. & Owen, F. (1979). Gamma-aminobutyric acid in the brain in schizophrenia. Lancet i, 560–561.CrossRefGoogle Scholar
Crow, T. J. (1978). Schizophrenia. The biochemistry of schizophrenia. British Journal of Hospital Medicine 20, 532–544.Google ScholarPubMed
Crow, T. J., Baker, H. F., Cross, A. J., Joseph, M. H., Lofthouse, R., Longden, A., Owen, F., Riley, G. J., Glover, V. & Killpack, W. S. (1979). Monoamine mechanisms in chronic schizophrenia: post-mortem neuro-chemical findings. British Journal of Psychiatry 134, 249–256.CrossRefGoogle Scholar
Curtis, D. R. (1979). GABA-ergic transmission in the mammalian central nervous system. In GABA-Neurotransmitters (ed. Krogsgaard-Larsen, P., Scheel-Kruger, J. and Kofod, H.), pp. 17–27. Munksgaard: Copenhagen.Google Scholar
Davis, K. E., Hollister, L. E. & Berger, P. A. (1976). Baclofen in schizophrenia. Lancet i, 1245.CrossRefGoogle Scholar
Flor-Henry, P. (1969). Psychosis and temporal lobe epilepsy. Epilepsia 10, 363–395.CrossRefGoogle ScholarPubMed
Gallo, V., Levi, G., Raiteri, M. & Coletti, A. (1981). Enhancement by GABA of glutamate depolarization-induced release from cerebellar nerve endings. Brain Research 205, 431–435.CrossRefGoogle ScholarPubMed
Gerlach, J., Rye, T. & Kristjansen, P. (1978). Effect of baclofen on tardive dyskinesia. Psychopharmacology 56, 145–151.CrossRefGoogle ScholarPubMed
Gold, G. I., Bowers, M. B., Roth, R. H. & Sweeney, D. W. (1980), GABA levels in CSF of patients with psychiatric disorders. American Journal of Psychiatry 137, 362–364.Google ScholarPubMed
Hare, T. A., Manyam, N. V. B. & Glaeser, B. S. (1980). Evaluation of cerebrospinal fluid γ-aminobutyric acid content in neurologic and psychiatric disorders. In Neurobiology of Cerebrospinal Fluid (ed. Wood, J. H.), p. 751. Plenum: New York.Google Scholar
Heath, R. G. (1954). Studies in Schizophrenia. Harvard University Press: Cambridge, Mass.CrossRefGoogle Scholar
Lautin, A., Angrist, B., Stanley, M., Gershon, S., Heckl, K. & Karobath, M. (1980). Sodium valproate in schizophrenia: some biochemical correlates. British Journal of Psychiatry 137, 240–244.CrossRefGoogle ScholarPubMed
Lees, A. J., Shaw, K. M. & Stern, G. M. (1978). Baclofen in Parkinson's disease. Journal of Neurology, Neurosurgery and Psychiatry 41, 707–708.CrossRefGoogle ScholarPubMed
Lichtshtein, D., Dobkin, J., Ebstein, R. P., Biederman, J., Rimon, R. & Belmaker, R. H. (1978). Gamma-aminobutyric acid (GABA) in the CSF of schizophrenic patients before and after neuroleptic treatment. British Journal of Psychiatry 132, 145–148.CrossRefGoogle ScholarPubMed
McCarthy, B. W., Gomes, U. R., Neethling, A. C., Shanley, B. C., Taljaard, J. J. F., Potgieter, L. & Roux, J. T. (1981). γ-Aminobutyric acid concentration in cerebrospinal fluid in schizophrenia. Journal of Neurochemistry 36(4), 1406–1408.CrossRefGoogle ScholarPubMed
McGeer, E. G. & McGeer, P. L. (1979). GABA-containing neurons in schizophrenia, Huntington's chorea and normal aging. In GABA-Neurotransmitters (ed. Krogsgaard-Larsen, P., Scheel-Kruger, J. & Kofod, H.), pp. 340–356. Munksgaard: Copenhagen.Google Scholar
McGeer, P. L., Brown, W. T. & Zeldowicz, L. (1977). Lack of effect of gamma-hydroxybutyrate in Huntington's chorea. Canadian Psychiatric Association Journal 22, 87–89.CrossRefGoogle ScholarPubMed
MacKay, A. V. P. (1980). Positive and negative schizophrenic symptoms and the role of dopamine. British Journal of Psychiatry 137, 379–386.CrossRefGoogle ScholarPubMed
Manyam, N. V. B., Katz, L., Hare, T. A., Gerber, J. C. & Grossman, M. H. (1980). Levels of γ-aminobutyric acid in cerebrospinal fluid in various neurologic disorders. Archives of Neurology 37, 352–355.CrossRefGoogle ScholarPubMed
Meldrum, B. S. (1975). Epilepsy and γ-aminobutyric acid-mediated inhibition. International Review of Neurobiology 17, 1–36. Academic Press: New York.Google Scholar
Meldrum, B. S. (1979). Convulsant drugs, anticonvulsants and GABA-mediated neuronal inhibition. In GABA-Neurotransmitters (ed. Krogsgaard-Larsen, P., Scheel-Kruger, J. and Kofod, H.), pp. 390–405. Munksgaard: Copenhagen.Google Scholar
Meldrum, B. (1981). Anticonvulsant drugs and GABA-mediated inhibition. In Psychopharmacology of Anticonvulsant drugs (ed. Sandler, M.). Oxford University Press: London.Google Scholar
Meldrum, B., Pedley, T., Horton, R., Anlezark, G. & Franks, A. (1980). Epileptogenic and anticonvulsant effects of GABA agonists and GABA uptake inhibitors. Brain Research Bulletin 5, Supplement 2, 685–690.CrossRefGoogle Scholar
Mitchell, P. R. & Martin, I. L. (1978). Is GABA release modulated by presynaptic receptors? Nature 274, 904–905.CrossRefGoogle ScholarPubMed
Olpe, H. R., Schellenberg, H. & Koella, W. P. (1977). Rotational behaviour induced in rats by intranigral application of GABA-related drugs and GABA antagonists. European Journal of Pharmacology 45, 291–294.CrossRefGoogle ScholarPubMed
Owen, F., Crow, T. J., Poulter, M., Cross, A. J., Longden, A. & Riley, G. J. (1978). Increased dopamine-receptor sensitivity in schizophrenia. Lancet ii, 223–226.CrossRefGoogle Scholar
Palfreyman, M. G., Schechter, P. J., Buckett, W. R., Tell, G. P. & Koch-Weser, J. (1981). The pharmacology of GABA-transaminase inhibitors. Biochemical Pharmacology 30, 817–824.CrossRefGoogle ScholarPubMed
Pepplinkuizen, L., Bruinvels, J., Blom, W. & Moleman, P. (1980). Schizophrenia-like psychosis caused by a metabolic disorder. Lancet i, 454–456.CrossRefGoogle Scholar
Perry, T. L., Buchanan, J., Kish, S. J. & Hansen, S. (1979). γ-aminobutyric-acid deficiency in brain of schizophrenic patients. Lancet i, 237–239.CrossRefGoogle Scholar
Perry, T. L., Wright, J. M., Hansen, S., Allan, B. M., Baird, P. A. & MacLeod, P. M. (1980). Failure of amino-oxyacetic acid therapy in Huntington's disease. Neurology 30, 772–775.CrossRefGoogle Scholar
Post, R. M., Fink, E., Carpenter, W. T. & Goodwin, F. K. (1975). Cerebrospinal fluid amine metabolites in acute schizophrenia. Archives of General Psychiatry 32, 1063–1069.CrossRefGoogle ScholarPubMed
Randrup, A. & Munkvad, I. (1972). Evidence indicating an association between schizophrenia and dopaminergic hyperactivity in the brain. Orthomolecular Psychiatry 1, 2–27.Google Scholar
Roberts, E. (1976). Disinhibition as an organizing principle in the nervous system. The role of the GABA system. Application to neurologic and psychiatric disorders. In GABA in Nervous System Function (ed. Roberts, E., Chase, T. N. and Tower, D. B.), pp. 515–539. Raven Press: New York.Google Scholar
Simpson, G. M., Branchey, M. H. & Shrivastana, R. K. (1976). Baclofen in schizophrenia. Lancet i, 966–967.CrossRefGoogle Scholar
Slater, E., Beard, A. W. & Glithero, E. (1963). The schizophrenia-like psychoses of epilepsy. British Journal of Psychiatry 109, 95–150.CrossRefGoogle Scholar
Spokes, E. G. S., Garrett, N. J., Rossor, M. N. & Iversen, L. L. (1980). Distribution of GABA in post-mortem brain tissue from control, psychotic and Huntington's chorea subjects. Journal of Neurological Sciences 48, 303–313.CrossRefGoogle ScholarPubMed
Stevens, J., Wilson, K. & Foote, W. (1974). GABA blockade, dopamine and schizophrenia: experimental studies in the cat. Psychopharmacologia (Berlin) 39, 105–119.CrossRefGoogle ScholarPubMed
Sweeney, V. P., Pathak, M. A. & Asbury, A. K. (1970). Acute intermittent porphyria. Increased ALA-synthetase activity during an acute attack. Brain 93, 369–380.CrossRefGoogle ScholarPubMed
Tamminga, C. A., Crayton, J. W. & Chase, T. N. (1978). Muscimol: GABA agonist therapy in schizophrenia. American Journal of Psychiatry 135, 746–747.Google ScholarPubMed
Tamminga, C. A., Crayton, J. W. & Chase, T. N. (1979). Suppression of involuntary movements in tardive dyskinesia by muscimol, a GABA agonist. Archives of General Psychiatry 36, 595–598.CrossRefGoogle Scholar
Tell, G., Böhlen, P., Schechter, P. J., Koch-Weser, J., Agid, Y., Bonnett, A. M., Coquillat, G., Chazot, G. & Fischer, C. (1981). Treatment of Huntington disease with γ-acetylenic GABA, an irreversible inhibitor of GABA transaminase: increased CSF GABA and homocarnosine without clinical amelioration. Neurology 31, 207–211.CrossRefGoogle ScholarPubMed
Van Kammen, D. P. (1977). γ-aminobutyric acid (GABA) and the dopamine hypothesis of schizophrenia. American Journal of Psychiatry 134, 138–143.Google ScholarPubMed
Van Praag, H. M. (1977). The significance of dopamine for the mode of action of neuroleptics and the pathogenesis of schizophrenics. British Journal of Psychiatry 130, 463–474.CrossRefGoogle Scholar
Waser, P. G. (1967). The pharmacology of amanita muscaria.In Ethnopharmacologic Search for Psychoactive Drugs. Proceedings of a Symposium held in San Francisco California,28–30 January 1967 (ed. Efron, D. H., Holmstedt, B. and Kline, N. S.), pp. 419–439.Google Scholar
Wolf, P., Olpe, H. R., Avrith, D. & Haas, H. L. (1978). GABA-ergic inhibition of neurons in the ventral tegmental area. Experientia 34, 73.CrossRefGoogle Scholar
Wood, J. H., Hare, T. A., Glaeser, B. S., Ballenger, J. C. & Post, R. M. (1979). Low cerebrospinal fluid γ-aminobutyric acid content in seizure patients. Neurology 29, 1203–1208.CrossRefGoogle ScholarPubMed
Yde, A., Lohse, E. & Faurbye, A. (1941). On the relation between schizophrenia, epilepsy and induced convulsions. Acta psychiatrica et neurologica scandinavica 16, 325–388.CrossRefGoogle Scholar